Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127906761 | 12790676 | 1 | I | 20110528 | 20110715 | 20160929 | 20160929 | EXP | US-ROCHE-790661 | ROCHE | 61.00 | YR | M | Y | 81.80000 | KG | 20160929 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127906761 | 12790676 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 28 DAYS; OVER 30-90 MINUTE ON DAY 1 AND 15. (10 MG/KG) ?LAST DOSE PRIOR TO SAE: 10 MAY 2011 | D | 125085 | 1740 | MG | SOLUTION FOR INFUSION | ||||||
| 127906761 | 12790676 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | D | 125085 | 1640 | MG | SOLUTION FOR INFUSION | |||||||
| 127906761 | 12790676 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | D | 125085 | 1674 | MG | SOLUTION FOR INFUSION | |||||||
| 127906761 | 12790676 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | D | 125085 | 784 | MG | SOLUTION FOR INFUSION | |||||||
| 127906761 | 12790676 | 5 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | D | 125085 | 1476 | MG | SOLUTION FOR INFUSION | |||||||
| 127906761 | 12790676 | 6 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | D | 125085 | 1500 | MG | SOLUTION FOR INFUSION | |||||||
| 127906761 | 12790676 | 7 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | D | 125085 | 830 | MG | SOLUTION FOR INFUSION | |||||||
| 127906761 | 12790676 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE 28 DAYS, ON DAYS 1, 8, 15 AND 22. LAST DOSE PRIOR TO SAE: 10 MAY 2011 | D | 0 | 100 | MG | |||||||
| 127906761 | 12790676 | 9 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 100 | MG | ||||||||
| 127906761 | 12790676 | 10 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 100 | MG | ||||||||
| 127906761 | 12790676 | 11 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 50 | MG | ||||||||
| 127906761 | 12790676 | 12 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 100 | MG | ||||||||
| 127906761 | 12790676 | 13 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 100 | MG | ||||||||
| 127906761 | 12790676 | 14 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 70 | MG | ||||||||
| 127906761 | 12790676 | 15 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | D | 0 | 20 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127906761 | 12790676 | 1 | Hepatocellular carcinoma |
| 127906761 | 12790676 | 8 | Hepatocellular carcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127906761 | 12790676 | DE |
| 127906761 | 12790676 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127906761 | 12790676 | Death | |
| 127906761 | 12790676 | Fatigue | |
| 127906761 | 12790676 | Hyponatraemia | |
| 127906761 | 12790676 | Lymphocyte count decreased | |
| 127906761 | 12790676 | Pain | |
| 127906761 | 12790676 | Platelet count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |